NCT03890952 is a Phase 2 clinical trial of Nivolumab in Recurrent Adult Brain Tumor, sponsored by Ulrik Lassen.

Who is sponsoring NCT03890952?

NCT03890952 is sponsored by Ulrik Lassen.

What drugs are being tested in NCT03890952?

Interventions in NCT03890952: Nivolumab, Bevacizumab.

What condition does NCT03890952 study?

NCT03890952 studies Recurrent Adult Brain Tumor.

Is NCT03890952 still recruiting?

NCT03890952 is currently completed. Last updated 24 July 2025.

Last reviewed 2025-07-24 · How we verify

NCT03890952

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent Glioblastoma

Completed Phase 2 Last updated 24 July 2025

What this trial tests

Phase 2 trial testing Nivolumab in Recurrent Adult Brain Tumor in 40 participants. Completed in 1 August 2024.

Timeline

1 October 2018

Primary endpoint
1 February 2023

1 August 2024

Quick facts

Lead sponsor	Ulrik Lassen
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	basic science
Enrollment	40
Start date	1 October 2018
Primary completion	1 February 2023
Estimated completion	1 August 2024
Sites	1 location across Denmark

Drugs / interventions tested

Nivolumab (nivolumab) — full drug profile →
Bevacizumab (Bevacizumab-Bvzr) — full drug profile →

Conditions studied

Recurrent Adult Brain Tumor — all drugs for Recurrent Adult Brain Tumor →

Sponsor

Ulrik Lassen — full company profile →

Who can join

18 and older, any sex, with Recurrent Adult Brain Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to make preliminary assessment of PD-L1 and other immune related biomarkers that might act as predictors of anti-tumor activity of Nivolumab in patients with recurrent glioblastoma

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Immunotherapy: a promising approach for glioma treatment.
Yasinjan F, Xing Y, Geng H, Guo R, et al · · 2023 · cited 156× · PMID 37744349 · DOI 10.3389/fimmu.2023.1255611
Glioblastoma at the crossroads: current understanding and future therapeutic horizons.
Singh S, Dey D, Barik D, Mohapatra I, et al · · 2025 · cited 91× · PMID 40628732 · DOI 10.1038/s41392-025-02299-4
Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade.
Peranzoni E, Ingangi V, Masetto E, Pinton L, et al · · 2020 · cited 60× · PMID 32793228 · DOI 10.3389/fimmu.2020.01590
Challenges to Successful Implementation of the Immune Checkpoint Inhibitors for Treatment of Glioblastoma.
Sanders S, Debinski W. · · 2020 · cited 50× · PMID 32316096 · DOI 10.3390/ijms21082759
CAR T cells and checkpoint inhibition for the treatment of glioblastoma.
Shen SH, Woroniecka K, Barbour AB, Fecci PE, et al · · 2020 · cited 46× · PMID 32027536 · DOI 10.1080/14712598.2020.1727436
Pathogenetic Features and Current Management of Glioblastoma.
Nguyen HM, Guz-Montgomery K, Lowe DB, Saha D. · · 2021 · cited 42× · PMID 33670551 · DOI 10.3390/cancers13040856
Receptor tyrosine kinases as druggable targets in glioblastoma: Do signaling pathways matter?
Qin A, Musket A, Musich PR, Schweitzer JB, et al · · 2021 · cited 37× · PMID 34806012 · DOI 10.1093/noajnl/vdab133
T lymphocyte-targeted immune checkpoint modulation in glioma.
Kelly WJ, Giles AJ, Gilbert M. · · 2020 · cited 33× · PMID 32051289 · DOI 10.1136/jitc-2019-000379

Verify or expand the search:

Other trials of Nivolumab

Trials testing the same drug.

NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
NCT07444619 — A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young A · Phase 1 · not yet recruiting
NCT07383441 — Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer · Phase 3 · not yet recruiting
NCT07420439 — Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease · Phase 2 · not yet recruiting
NCT07510334 — VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma · Phase 2 · not yet recruiting

Other recruiting trials for Recurrent Adult Brain Tumor

Currently open trials in the same condition.

NCT06273176 — The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma · recruiting

Other Ulrik Lassen trials

Trials by the same sponsor.

NCT04341181 — ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03890952 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ulrik Lassen
Last refreshed: 24 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03890952.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing